Literature DB >> 12967932

Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat.

Mohamed Abdouh1, Ashraf Khanjari, Nadia Abdelazziz, Brice Ongali, Réjean Couture, Haroutioun M Hasséssian.   

Abstract

(1) Retinal microvessel responses to kinin B1 and B2 receptor agonists and antagonists were investigated in streptozotocin (STZ)-diabetic rats and age-matched controls. In addition, quantitative in vitro autoradiography was performed on retinas from control and STZ-diabetic rats with radioligands specific for B2 ([125I]HPP-Hoe 140), and B1 receptors ([125I]HPP-[des-Arg10]-Hoe 140). (2) In control rats, the B2 receptor agonist bradykinin (BK, 0.1-50 nm) vasodilated retinal vessels in a concentration and time-dependent manner. This effect was completely blocked by the B2 receptor antagonist Hoe140 (1 microm). In contrast, the B1 receptor agonist des-Arg9-BK (0.1-50 nm) was without effect. (3) Des-Arg9-BK was able to produce a concentration-dependent vasodilatation as early as 4 days after STZ injection, and the effect of 1 nm des-Arg9-BK was inhibited by the B1 receptor antagonist des-Arg10-Hoe140 (1 microm). Low-level B1 receptor binding sites were detected in control rats, but densities were 256% higher in retinas from 4- to 21-day STZ-diabetic rats. (4) In control rats, the vasodilatation in response to 1 nm BK involved neither calcium influx nor nitric oxide (NO) as GdCl3 and l-NAME were without effect. However, the vasodilatation did involve intracellular calcium mobilization as well as products of the cyclooxygenase-2 (COX-2) pathway as 2,5-di-t-butylhydroquinone (BHQ), cADP ribose and l-745 337 inhibited this response. The vasodilatation response was blocked by trans-2-phenyl cyclopropylamine (TPC) demonstrating that prostacyclins mediate this response. (5) In STZ-diabetic rats, the vasodilatation in response to des-Arg9-BK involved both calcium influx and intracellular calcium mobilization from stores both IP3 sensitive and non-IP3 sensitive. Indeed, the effect was blocked by GdCl3, BHQ and cADP ribose. Furthermore, NO production and products of the COX-2 pathway including prostacyclin are involved as the response was inhibited by l-NAME, l-745 377 and TPC. (6) Vasodilatation in response to either 1 nm BK or 1 nm des-Arg9-BK were blocked by NF023 demonstrating that a Go/Gi G-protein transduces both these effects. (7) This is the first report on the retinal circulation which provides evidence for vasodilator B2 receptors and the upregulation of B1 receptors very early following induction of diabetes with STZ rats. These results suggest that kinin receptors may be potential targets for therapeutics to treat retinopathies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967932      PMCID: PMC1573993          DOI: 10.1038/sj.bjp.0705210

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  An inducible cytoplasmic factor (AU-B) binds selectively to AUUUA multimers in the 3' untranslated region of lymphokine mRNA.

Authors:  P R Bohjanen; B Petryniak; C H June; C B Thompson; T Lindsten
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

2.  DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist.

Authors:  K Wirth; G Breipohl; J Stechl; J Knolle; S Henke; B Schölkens
Journal:  Eur J Pharmacol       Date:  1991-11-26       Impact factor: 4.432

3.  [Activity of tissue and plasma kallikrein and level of their precursors in eye tissue structures and media of healthy rabbits].

Authors:  T P Kuznetsova; N B Chesnokova; T S Paskhina
Journal:  Vopr Med Khim       Date:  1991 Jul-Aug

4.  Expression and cellular localization of the kallikrein-kinin system in human ocular tissues.

Authors:  J X Ma; Q Song; H C Hatcher; R K Crouch; L Chao; J Chao
Journal:  Exp Eye Res       Date:  1996-07       Impact factor: 3.467

5.  Roles for interleukin-1beta, phorbol ester and a post-transcriptional regulator in the control of bradykinin B1 receptor gene expression.

Authors:  X Zhou; P Polgar; L Taylor
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

Review 6.  Cyclic ADP-ribose: a new way to control calcium.

Authors:  A Galione
Journal:  Science       Date:  1993-01-15       Impact factor: 47.728

Review 7.  Kinin receptors in pain and inflammation.

Authors:  R Couture; M Harrisson; R M Vianna; F Cloutier
Journal:  Eur J Pharmacol       Date:  2001-10-19       Impact factor: 4.432

8.  Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation.

Authors:  Marilyne Mage; Christiane Pécher; Eric Neau; Eric Cellier; Marina L Dos Reiss; Joost P Schanstra; Réjean Couture; Jean-Loup Bascands; Jean-Pierre Girolami
Journal:  Can J Physiol Pharmacol       Date:  2002-04       Impact factor: 2.273

Review 9.  Bradykinin receptors.

Authors:  J M Hall
Journal:  Gen Pharmacol       Date:  1997-01

10.  Exposure to elevated D-glucose concentrations modulates vascular endothelial cell vasodilatory response.

Authors:  W F Graier; T C Wascher; L Lackner; H Toplak; G J Krejs; W R Kukovetz
Journal:  Diabetes       Date:  1993-10       Impact factor: 9.461

View more
  17 in total

1.  Plasma kallikrein and diabetic macular edema.

Authors:  Edward P Feener
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

Review 2.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

3.  Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.

Authors:  Ashay D Bhatwadekar; Viral S Kansara; Thomas A Ciulla
Journal:  Expert Opin Investig Drugs       Date:  2020-01-31       Impact factor: 6.206

Review 4.  Diabetic retinopathy: Breaking the barrier.

Authors:  Randa S Eshaq; Alaa M Z Aldalati; J Steven Alexander; Norman R Harris
Journal:  Pathophysiology       Date:  2017-07-12

Review 5.  Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.

Authors:  Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

6.  Expression, distribution and function of kinin B1 receptor in the rat diabetic retina.

Authors:  Soumaya Hachana; Menakshi Bhat; Jacques Sénécal; Frédéric Huppé-Gourgues; Réjean Couture; Elvire Vaucher
Journal:  Br J Pharmacol       Date:  2018-02-13       Impact factor: 8.739

7.  The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance.

Authors:  J P Dias; M A Ismael; M Pilon; J de Champlain; B Ferrari; P Carayon; R Couture
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

Review 8.  Plasma kallikrein-kinin system and diabetic retinopathy.

Authors:  Jia Liu; Edward P Feener
Journal:  Biol Chem       Date:  2013-03       Impact factor: 3.915

9.  Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors.

Authors:  M Abdouh; S Talbot; R Couture; H M Hasséssian
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

10.  Cellular localization of kinin B1 receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [Nalpha-Bodipy]-des-Arg9-bradykinin.

Authors:  Sébastien Talbot; Patrick Théberge-Turmel; Dalinda Liazoghli; Jacques Sénécal; Pierrette Gaudreau; Réjean Couture
Journal:  J Neuroinflammation       Date:  2009-03-26       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.